Hunter Syndrome (MPS II)

This is another rare genetic disorder. It's caused by a missing enzyme that breaks down sugars. This leads to the sugars building up in the body, causing physical and mental health issues. It's different from MPS I because it usually doesn't cause blindness and is inherited differently.

Condition

What people with Hunter Syndrome (MPS II) report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Hunter Syndrome (MPS II)?

NameHow it went

About Hunter Syndrome (MPS II)

What It Is

Hunter syndrome, also called mucopolysaccharidosis type II (MPS II), is a rare inherited condition in which the body cannot break down certain complex sugar molecules called glycosaminoglycans (GAGs). The molecules build up inside cells throughout the body, gradually enlarging and stiffening tissues and organs. It affects almost only boys and men. Babies with Hunter syndrome usually look healthy at birth. Signs typically appear between about 18 months and 4 years of age: fuller lips and cheeks with a broad nose and enlarged tongue, a deep hoarse voice, frequent ear and breathing infections, loud snoring, an enlarged liver and spleen, hernias around the belly button or groin, and stiff joints. Growth slows after early childhood. Over the years the condition can also affect hearing, the airway, the heart valves, the spine and the nerves in the wrists. Doctors describe two broad forms along a spectrum. In the severe (neuronopathic) form, the brain is affected too: development slows and children gradually lose skills they had gained, often from around age 6 to 8. In the attenuated (non-neuronopathic) form, thinking and intelligence are usually unaffected, although the effects on the rest of the body can still be serious.

Causes & Risk Factors

Hunter syndrome is caused by changes (variants) in the IDS gene, which carries the instructions for an enzyme called iduronate-2-sulfatase (I2S). Lysosomes, the compartments that digest and recycle material inside cells, need this enzyme to break down GAGs. When I2S is missing or works poorly, GAGs accumulate and slowly damage tissues. The IDS gene sits on the X chromosome, which explains who is affected. Boys have one X chromosome, so a single altered copy is enough to cause the disease. Girls and women have two X chromosomes and are usually carriers without symptoms, although a few affected females have been reported. A mother who carries the variant has a 50% chance of passing it on in each pregnancy: a son who inherits it will be affected, and a daughter who inherits it will usually be a carrier. An affected man passes the variant to all of his daughters and none of his sons.

How It's Diagnosed

In the United States, MPS II was added to the federal Recommended Uniform Screening Panel for newborns in 2022, and many state programs now test for it in the heel-prick blood sample taken shortly after birth. Not every state screens for it yet, so many children are still diagnosed only after symptoms appear, often after a long search for an explanation. A positive newborn screen is not a diagnosis. The first test measures I2S enzyme activity, and low readings in healthy babies (called pseudodeficiency) are much more common than true Hunter syndrome. Programs therefore check GAG levels as a second step and refer a baby with abnormal results to a genetics specialist for confirmation. The diagnosis is confirmed by finding absent or very low I2S activity in a blood sample, with normal activity of a second, related enzyme to rule out a different disorder, or by finding a disease-causing IDS variant on genetic testing. Raised GAG levels in urine support the diagnosis. Genetic results do not always predict how severe the condition will be, but they make family testing possible: male relatives at risk can be checked early, before symptoms, and female relatives can learn whether they are carriers.

Treatment Options

There is no cure, but treatment can slow the disease and ease many of its effects. Specialists recommend starting as soon as possible after diagnosis, because most damage that has already happened, especially in the brain and skeleton, cannot be reversed. Enzyme replacement therapy (ERT) supplies a manufactured version of the missing enzyme through an intravenous infusion once a week. Idursulfase (Elaprase) has been the standard ERT since 2006. It has been shown to improve walking ability in people 5 and older, and studies link it to better lung function and survival. In younger children it shrinks an enlarged spleen, but evidence on long-term outcomes at that age is limited. Tividenofusp alfa (Avlayah), approved in the US in 2026, is an enzyme therapy engineered to cross from the bloodstream into the brain. It is approved for children weighing at least 5 kg (about 11 pounds) whose brain is or is expected to be affected, when started before advanced neurologic impairment. Its approval was accelerated, based on lowering a disease marker in spinal fluid, so trials still need to show how much it protects thinking and development. It is used instead of idursulfase, not alongside it. Infusions take several hours every week on an ongoing basis. Reactions during or after an infusion are fairly common, so infusions are given where staff can treat a severe reaction, and some people receive medicines beforehand to prevent them. Serious allergic reactions can occur early in treatment or after years of it. Avlayah also requires blood tests for anemia and checks of kidney function. A hematopoietic stem cell transplant (bone marrow or cord blood transplant) gives the body donor cells that keep making the enzyme, and it has been considered for some children with the severe form. It carries a real risk of death from transplant complications, and experts have not reached agreement on when to use it. Gene therapies are in clinical trials but are not commercially available. Supportive care is a large part of treatment: ear tubes and hearing aids, removal of tonsils and adenoids, CPAP (a machine that keeps the airway open during sleep), physical and occupational therapy, hernia repair, carpal tunnel surgery, a shunt to drain excess fluid from the brain, heart valve care, educational support and help for the whole family. Care is usually coordinated by a metabolic or genetics center experienced with MPS.

What to Expect

Hunter syndrome is progressive, and its course varies widely from one person to another, although affected relatives often follow a similar pattern. In the severe form, children typically lose skills from early school age and need more and more care; life expectancy has historically been about 10 to 20 years. People with the attenuated form usually live into adulthood with normal intelligence, some into their 60s, but face growing problems with the airway, heart, joints, hearing and mobility. Heart and airway disease are the main causes of death in both forms. How much earlier diagnosis and newer treatments change these figures is still being learned. Daily life is shaped by weekly infusions and a team of specialists. Regular checks usually include heart ultrasounds, hearing tests, breathing tests, and eye, bone and joint, and developmental reviews about once a year, dental visits every six months, and sleep studies when needed. Sleep problems are common, and children with the severe form often have behavioral challenges. The practical, emotional and financial load on families can be heavy; genetic counseling, social work, school supports and patient advocacy groups can help. Surgery and sedation need advance planning. An enlarged tongue, narrowed airway and stiff neck can make anesthesia and placing a breathing tube difficult, so procedures, including dental work under sedation, are best done at centers familiar with MPS.

When to Seek Help

Ask about a genetics evaluation if a young child has several of these features together: coarsening facial features, an enlarged belly from a large liver or spleen, stiff joints, hernias, repeated ear infections with loud snoring, or slowing development, especially when a male relative had MPS II. If a newborn screen is positive, go to the follow-up testing promptly; it is often a false alarm, but early treatment matters if it is confirmed. Contact the care team promptly about a fever or chest infection before a scheduled infusion, since the infusion may need to be delayed, and about new weakness, numbness or clumsiness in the arms or legs, which can signal pressure on the spinal cord in the neck. Let the team know well before any planned surgery or sedation. Serious allergic reactions (anaphylaxis) to enzyme infusions can happen during an infusion or up to 24 hours afterward. If trouble breathing, swelling of the lips, tongue or throat, widespread hives, or faintness develops after leaving the infusion center, call 911.

Questions to Ask Your Doctor

  1. 1.Does my child appear to have the severe or the attenuated form, and how certain can we be at this stage?
  2. 2.Which treatment do you recommend, and what results are realistic with each option, including a transplant or a clinical trial?
  3. 3.What needs to be arranged before any surgery, sedation or dental procedure?
  4. 4.Which family members should be offered carrier or diagnostic testing?
  5. 5.Who will coordinate care among the specialists, and what support is available for our family?

Last reviewed • Oct 2026

Educational content, not medical advice.